Prihlásiť sa Zaregistrujte sa zadarmo

Budúce P/E spoločnosti Alimera Sciences

Aká je hodnota metriky Budúce P/E spoločnosti Alimera Sciences?

Hodnota metriky Budúce P/E spoločnosti Alimera Sciences Inc. je -8.47

Aká je definícia metriky Budúce P/E?



Budúci pomer P/E (Forward price to earnings ratio) vyjadruje pomer súčasnej ceny a odhadovaného zisku na akciu za ďalších 12 mesiacov.

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

Budúce P/E spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Alimera Sciences

Čomu sa venuje spoločnosť Alimera Sciences?

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.

Firmy s metrikou budúce p/e podobnou spoločnosti Alimera Sciences